PNC Financial Services Group Inc. Has $3.63 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

PNC Financial Services Group Inc. increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,669 shares of the medical device company's stock after purchasing an additional 8,257 shares during the period. PNC Financial Services Group Inc.'s holdings in DexCom were worth $3,629,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Private Trust Co. NA boosted its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Heck Capital Advisors LLC acquired a new stake in DexCom during the fourth quarter worth approximately $38,000. SBI Securities Co. Ltd. bought a new position in DexCom during the 4th quarter worth $49,000. Finally, Midwest Capital Advisors LLC acquired a new position in DexCom in the 4th quarter valued at $54,000. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on DXCM shares. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Citigroup increased their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $99.82.

Remove Ads

DexCom Trading Up 0.9 %

NASDAQ:DXCM traded up $0.66 during mid-day trading on Monday, hitting $71.35. 3,626,701 shares of the company's stock were exchanged, compared to its average volume of 3,887,451. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $27.88 billion, a P/E ratio of 49.90, a PEG ratio of 2.30 and a beta of 1.28. The company has a 50 day simple moving average of $83.99 and a 200-day simple moving average of $76.93.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,657 shares of company stock valued at $8,019,422 over the last ninety days. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.